Table 2.
Baseline characteristics of the 31 enrolled patients.
| Variable | Dipyridamole group (n = 14) | Control group (n = 17) |
|---|---|---|
| General characteristic | ||
| Age (yr)—mean±SD (range) | 56 ± 12 (32–74) | 56 ± 15 (23–74) |
| Gender—male no./female no. | 8/6 | 13/4 |
| Group | ||
| Non-severe no./Severe no./Critical no. | 4/8/2 | 3/12/2 |
| Clinical variables | ||
| Cough—no. (%) | 14 (100.0%) | 17 (100.0%) |
| Shortness of breath—no. (%) | 11 (78.6%) | 13 (76.5%) |
| Nausea and vomiting—no. (%) | 8 (57.1%) | 6 (35.3%) |
| Systolic blood pressure (mmHg)—mean±SD (range) | 127 ± 12 (120–155)/81 ± 11 (57–124) | 128 ± 13 (107–153)/78 ± 10 (56–96) |
| Partial pressure of oxygen (mmHg)—mean±SD (range) | 86 ± 12 (58–93) | 92 ± 9 (76–96) |
| Laboratory values | ||
| Lymphocyte (109/L)—mean±SD (range) | 1.07 ± 0.57 (0.29–2.28) | 0.82 ± 0.45 (0.17–1.85) |
| Decrease in concentrations of lymphocyte—no. (%) | 9 (64.3%) | 12 (70.6%) |
| —no. of non-severe cases (%) | 1/4 (25%) | 2/3 (66.7%) |
| —no. of severe cases (%) | 7/8 (87.5%) | 9/12 (75%) |
| —no. of critical cases (%) | 1/2 (50%) | 1/2 (50%) |
| D-dimer (mg/L)—mean±SD (range) | 2.00 ± 2.54 (0.19–6.84) | 1.50 ± 2.73 (0.01–8.43) |
| Increase in concentrations of D-dimer—no. (%) | 6/14 (42.9%) | 5/17 (29.4%) |
| —no. of non-severe cases (%) | 1/4 (25%) | 0 |
| —no. of severe cases (%) | 4/8 (50%) | 5/12 (41.7%) |
| —no. of critical cases (%) | 1/2 (50%) | 0 |
| Respiratory pathogens | ||
| The nucleic acid of SARS-CoV-2—no. (%) | 14 (100.0%) | 17 (100.0%) |
| Unilateral pneumonia—no. (%) | 0 | 1 (5.9%) |
| Bilateral pneumonia—no. (%) | 14 (100.0%) | 16 (94.1%) |
| Comorbidities | ||
| Diabetes mellitus—no. (%) | 3 (21.4%) | 1 (5.9%) |
| Cardiovascular disease—no. (%) | 2 (14.3%) | 3 (17.6%) |
| Cerebrovascular disease—no. (%) | 1 (7.1%) | 2 (11.8%) |